| Ondansetron | |||
Suspect drug use if your child has lately become very irritable, unpleasant to or bullying of other family members, very easy to provoke, starts to use a lot of profanity seems tired, worn out and apathetic a lot of the time, or develops a nagging cough, appears to have the sniffles or runny nose, or develops nosebleeds frequently.
Ondansetron 8mg tabPALLIATIVE CARE TIPS - Anna W. Taube, MD, Capital Health Regional Palliative Care Program, Grey Nuns Community Hospital - Issue #5 Collect them all ; July 2005 ; CANCER NAUSEA AND VOMITING: Nausea often multi factorial ; occurs in 60% of patients Vomiting in some 30% ETIOLOGIES: * COMMONEST ; 1. GI: a ; * constipation obstipation b ; * gastric stasis opioid, cancer anorexia-cachexia syndrome known to cause autonomic nervous system dysfunction ; , hepatomegaly, ascites, abdominal tumor masses ; c ; * complete partial obstruction esophagus may be intrinsic or extrinsic upper lower bowel usu. extrinsic d ; gastritis duodenitis ulcer disease NSAID, alcohol, Helicobacter p. ; e ; oro-naso- pharyngeal disease poor hygiene, H&N fungating tumors, oropharyngeal esophageal Candida ; 2. Metabolic: * hypercalcemia; uremia 3. * Drugs: either Chemoreceptor Trigger Zone CTZ ; stimulation or GI irritation ; : opioids; NSAID's; digoxin; antibiotics 4. CNS: * metastases increased ICP ; : vestibular pathology 5. Radiation: to abdomen, pelvis or brain 6. Chemotherapy: esp. Cisplatin, Cyclophosphamide, Doxorubicin, Dacarbazine 7. Psychogenic: food odors, etc. MANAGEMENT: COMMONEST ETIOLOGIES GENERAL: 1. If possible: i ; Treat underlying cause if patients overall condition warrants eg. hypercalcemia ; ii ; Stop decrease change offending drugs or other triggers ; iii ; Avoid sedating drugs eg. dimenhydrinate, prochlorperazine ; 2. SC route for meds hydration avoid IM IV if possible ; if N V significantly interfering with po route SPECIFIC: A ; Constipation Obstipation: See Issue #3 COMMON AND VERY IMPORTANT CAUSE ; B ; Gastric stasis: i ; regardless of etiology, metoclopramide is drug of choice dual action: central inhibition of dopamine receptors in brainstem CTZ & peripheral gastric motility stimulation ; : 10-20mg po sc q1h prn to q4h around the clock & q1h prn if intermittent sc ineffective, trial continuous sc infusion CSCI ; to 60-120mg 24h. ii ; if CSCI metoclopramide ineffective, trial dexamethasone 10mg bid po sc x 24hr: then decrease to lowest effective dose iii ; if metoclopramide not tolerated extrapyramidal side-effects ; trial other prokinetic drug: domperidone 10 - 20mg po only ; tid ac & qhs iv ; if domperidome ineffective, trial ondansetron 8 mg po sc q8h usually more effective for chemo-induced nausea but occasionally helpful ; C ; Bowel Obstruction: Always consider surgery; if surgery not an option: a ; no prokinetic agents: may cause reverse peristalsis & increase emesis i ; complete: b ; dexamethasone 10mg sc qid x 24h; if effective, decrease by 10mg qd to lowest effective dose may reduce tumor-induced edema & reopen GI lumen: also extremely powerful antiemetic ; c ; steroid ineffective?: trial haloperidol 1-2mg sc q12h & q1h prn d ; haloperidol ineffective? consider hyoscine butylbromide 10-20mg sc q4h or 60-120mg 24h by CSCI or octreotide 100 g sc bid to tid decrease GI secretions and motility ; e ; conservative sc hydration 1-2 L d; minimize GI secretions ; & sc opioid for pain f ; NG tube only if copious vomiting abdominal distention & only till distention resolved g ; obstruction unresolved: consider decompression PEG allows fluid intake for pleasure ; h ; esophageal obstruction: consider stent dilation A patient can live for weeks to months on sc hydration drug administration ii ; partial: a ; prokinetic agent, stool softener & vigorous use of enemas: impacted feces in narrowed lumen may be obstructing agent b ; b, c, e, f & h, as above, until obstruction resolves D ; Hypercalcemia: hydration & bisphosphonate E ; Drugs: change opioid if other measures ineffective F ; CNS mets: dexamethasone 4mg po sc qid; palliative radiation if overall condition warrants. Was significant for drinks per day P .006 ; with the patients with earlyonset alcoholism in the ondansetron 4 g kg twice per day dosage group being superior to placebo P .001. Ondansetron was not mutagenic in standard tests for mutagenicity. Specialty injectable drugs establish their place in medicine and in the pharmacy benefit as more plan sponsors seek to manage the costs of these high-priced drugs and zofran. Table 7. Adjusted Cost Rates and Rate Ratios, CAP Diagnosis. According to grading of Trey, Burns, and Saunders 1966 ; Patients with Poor Sparteine Debrisoquine Metabolism There were no significant differences among poor and extensive debrisoquine categorised metabolisers with regard to ondansetron disposition area under the curve, total systemic clearance, elimination half-life ; following a single 8 mg intravenous dose. The effect of repeated dosing was not investigated, nevertheless dosage adjustments will probably not be required in patients receiving ondansetron by either the oral or intravenous route. COMPATIBILITY WITH OTHER DRUGS: Administration recommendations: slow intravenous injection from an infusion bag or syringe pump. The following drugs may be administered via the Y-site of the ondansetron giving set for ondansetron concentrations of 16 to 160 micrograms mL ie. 8 mg 500 mL and 8 mg 50 mL respectively ; . Cisplatin: Concentrations up to 0.48 mg mL ie. 240 mg in 500 mL ; administered over one to eight hours. 5-fluorouracil: Concentrations up to 0.8 mg mL ie 2.4 g in 3 litres or 400 mg in 500 mL ; administered at a rate of at least 20 mL per hour 500 mL per 24 hours ; . Higher concentrations of 5-fluorouracil may cause precipitation of ondansetron. The 5-fluorouracil infusion may contain up to 0.045% w v magnesium chloride in addition to other excipients shown to be compatible. Carboplatin: Concentrations in the range 0.18 mg mL to 9.9 mg mL ie 90 mg in 500 mL to 990 mg in 100 mL ; , administered over ten minutes to one hour. Etoposide: Concentrations in the range 0.14 mg mL to 0.25 mg mL ie 72 mg in 500 mL to 250 mg in 1 litre ; , administered over thirty minutes to one hour. Ceftazidime : Doses in the range 250 mg to 2000 mg reconstituted with Water for Injections BP as recommended by the manufacturer ie 2.5 mL for 250 mg and 10 mL for 2 g ceftazidime ; and given as an intravenous bolus injection over approximately five minutes. Cyclophosphamide: Doses in the range 100 mg to 1 g, reconstituted with Water for Injections BP, 5 mL per 100 mg cyclophosphamide, as recommended by the manufacturer, and given as an intravenous bolus injection over approximately five minutes. Doxorubicin: Doses in the range 10-100 mg reconstituted with Water for Injections BP, 5 mL per 10 mg doxorubicin, as recommended by the manufacturer and given as an intravenous bolus injection over approximately five minutes and oxcarbazepine. Itching is a common symptom experienced by people with hepatitis. In small surveys, anywhere from 20-50% of people with chronic hepatitis reported itching as a symptom of their disease. The medical term for itching is pruritus, and there are many different causes for this symptom. For some, this symptom is a minor annoyance. However, those with intense itching can experience nervousness, anxiety, irritability, and sleeplessness that disrupt their normal daily activities. I will review some causes of itching among people with chronic hepatitis, and give some tips about what you can do if you are suffering from this vexing problem. What is an itch? Special nerve fibers in the skin called Cfibers relay signals from the skin to the spinal cord and brain. C-fibers are responsible for transmitting the sensation of itching, and also carry pain signals. When C-fibers are stimulated, substances called neurotransmitters are released. The release of neurotransmitters can lead to a cascade of reactions that intensify the itch sensation and may cause redness and swelling in the area where the itch is felt. Outside of allergic reactions, the causes of C-fiber stimulation that lead to itching are not well understood. Whatever the process that causes itching, we all know well that itching leads to scratching. However, scratching for someone with chronic pruritus is counterproductive. Scratching tends to intensify the itch sensation beginning an itch-scratch-itch cycle. Intense itching can cause even the. Prophylaxis in the hypothetical patient vignettes a 5HT3 antagonist, droperidol, dexamethasone, and metoclopramide were intended to represent major receptor systems involved in the etiology of PONV, as well as agents commonly used in clinical practice. We did not specify the doses of the four chosen antiemetics because we were mainly interested in the choice not the dose. To keep survey length reasonable, we opted not have a vignette with promethazine as a prophylaxis agent because in our outpatient practice promethazine is infrequently given for prevention. Two-thirds of the anesthesiologists reported they would administer a 5-HT3 antagonist as first choice for PONV treatment if no prophylaxis had been given. The efficacy of the 5-HT3 antagonists may be more pronounced when a patient is vomiting than as treatment for nausea. There is weak evidence of dose-responsiveness with these drugs [22, 23]. Therefore, small doses of the 5-HT3 antagonists ondansetron 1 mg ; have been recommended for treatment. Interestingly, less than 15% of anesthesiologists reported using a combination of several agents for treatment, despite that combination of agents, or multi-modal therapy, may be increasingly being used for prophylaxis and trileptal. Ondansetron pediatric dosageThe drug affects brain pathways that are related to the drive for drinking. A. ADULTS To protect the rights and interests of both the adult patient and the hospital, appropriate signed consents must be obtained before examination, treatment, and evidence collection begins. 1. Consent to medical examination and treatment only General consent for routine diagnostic and medical procedures, informed consent for more complex procedures, and consent for emergency treatment must be obtained in accordance with hospital policy. $ At the onset of the consent interview, the patient must be informed that examination and treatment for injuries inflicted in violation of any state penal law obligates the hospital and health practitioner to make a telephone and written report to the local law enforcement agency. 2. Consent to medical examination, collection and preservation of evidence If the patient consents to the medical examination for collection of evidence, the Patient Consent section for patients age 12 and older ; on the required forms must be signed. This indicates the patient understands that evidence will be collected, preserved, and released to law enforcement authorities. $ Patients must be given the following information: $ Patients have the right to refuse an examination for the purpose of collecting evidence. $ Consent for evidence collection, once given, can be withdrawn at any time for all or part of the examination. Once evidence has been collected, however, and given to the law enforcement agency or to the crime lab, it is no longer under the patient's control. $ Evidence includes photographs of injuries and these photographs may include the genital area. $ Patients have the right to refuse the collection of reference specimens, such as pubic and head hair; blood and or saliva for typing; and blood and or urine for toxicology analysis. $ If the patient does not permit collection of reference specimen s ; at the time of the examination or at a later date, the crime laboratory cannot conduct a comparative analysis of the evidence in question. $ Physical evidence deteriorates and will be unobtainable if not collected and preserved promptly. $ The cost of an evidential examination is the responsibility of the local law enforcement agency only if the patient consents to the collection of 6 and paroxetine. Presynaptic properties and postsynaptic targets of peptidergic nociceptive primary afferents that express HCN channel subunit 2 in laminae I-II of the spinal dorsal horn in rats Papp Ildik, Veress Gbor, Antal Mikls Department of Anatomy, Histology and Embryology, Faculty of Medicine, Medical Health and Science Center, University of Debrecen, Debrecen pildiko chondron.anat.dote.hu Neurons possess a rich variety of voltage- and ligand-gated ion channels, including hyperpolarizationactivated and cyclic nucleotide-gated channels HCN ; , that are usually activated during membrane hyperpolarization following the termination of action potentials and provide a mixed inward Na + K current that slowly depolarizes the plasma membrane. In our previous study we have demonstrated that HCN channel subunit 2 HCN2 ; is expressed by terminals of peptidergic nociceptive primary afferents in laminae I-IIo of the rat spinal dorsal horn. In the present experiment we investigated the presynaptic chemical properties and postsynaptic targets of these HCN2-expressing primary afferent terminals, using double and triple labeling immunocytochemical methods for confocal microscopy. We have demonstrated that most of the HCN2-expressing primary afferent terminals are also immunoreactive for substance-P SP ; . These double labeled terminals contact spinal neurons that express neurokinin-1 receptor NK1-R ; , the receptor of SP. Investigating the co-localization of HCN2 and vesicular glutamate transporters VGluT1-3 ; , we found that HCN2 immunoreactivity is completely segregated from VGluT1 and VGlut3, and for some reason the co-localization between HCN2 and VGluT2 was also very weak. We have also demonstrated that only a small proportion of HCN2-IR terminals show positive immunostaining for MOR and GABAB2-R. Investigating the postsynaptic targets of HCN2-expressing primary afferents we found that HCN2-IR terminals frequently contact spinal neurons that express NK1-receptor, calbindin D28k, GluR2 subunit of AMPA receptors and MOR, for instance, ondansetron hyperemesis. 2006 oct; 10 7 ; : 629-3 stamer um, stuber analgesic efficacy of tramadol if coadministered with ondansetron and prandin. It is also recommended for all health care personnel, for instance, ondansetron odt 4. On 28 October 2005, the Food and Drug Administration FDA ; approved a new formulation of Kaletra. Kaletra lopinavir ritonavir ; is now available in the US as a film-coated tablet 200mg 50mg ; that provides advantages over the currently marketed capsule formulation for HIV-1 infected patients. Specifically, the tablet formulation: does not require refrigeration, can be administered without regard to meals and repaglinide. They would have to approach their GP and tell them that they had not ordered their prescription in time. Within a few months he received no more requests for emergency supplies for late requests. Neil Heslop and Adam Todd ibid, p104 ; in their letter that berates those pharmacists who do not supply, say that "emergency" is open to interpretation and urge us to view a pharmaceutical emergency as something different from a medical emergency. Surely, in the above case, it is better to have people ordering their prescriptions in time rather than waiting to see if they can get an emergency supply. In this way the pharmacist has almost removed pharmaceutical emergencies and therefore cut down greatly on the chances of a medical emergency. Another pharmacist, on taking over a pharmacy, said that no loans were to be made and all emergency supplies must be paid for.Again, emergency requests dropped substantially within a few months. The authors raise three points, which they believe are incorrectly believed to be true. Ondansetron manufacturerJames Chalmers lectures in law at the University of Aberdeen. His articles on the criminalisation of HIV transmission have appeared in the Journal of Medical Ethics, the Juridical Review and Sexually Transmitted Infections and prograf and ondansetron, for example, ondanset5on im. The study listed may include approved and non-approved uses, formulations or treatment regimens. The results reported in any single study may not reflect the overall results obtained on studies of a product. Before prescribing any product mentioned in this Register, healthcare professionals should consult prescribing information for the product approved in their country. Study No.: S3AV05 Title: A randomized, double blind, parallel group study to compare the efficacy and tolerability of onddansetron vs metoclopramide in the prevention of post-operative nausea and vomiting in patients undergoing ophthalmic surgery Rationale: The incidence of PONV post-operative nausea and vomiting ; has been reported to vary from 30 to 80% in subjects undergoing ophthalmic surgery with general anaesthesia. Ondansetronn has been shown to be effective in reducing PONV following ophthalmic surgery. This study was undertaken to compare the efficacy ondansdtron versus metoclopramide, in subjects who are candidates for ophthalmic surgery executed under general anaesthesia. Phase: III B Study Period: May 1995-May 1996 Study Design: Randomized, parallel group, double blind, comparative study Centers: 2 centers in Italy Indication: Post-operative Nausea and Vomiting Treatment: Study treatment, ondansetron 4 mg or metoclopramide 10 mg, was administrated intravenously prior to induction anaesthesia. Objectives: The primary objective of this study was to compare the efficacy of ondansetron 4 mg single intravenous iv ; dose vs metoclopramide 10 mg single intravenous dose in the prevention of post-operative nausea and vomiting in subjects undergoing ophthalmic surgery. Primary Outcome Efficacy Variable: The primary efficacy variable was the proportion of subjects with no emetic episodes during the 24 hours after recovery from anaesthesia. Secondary Outcome Efficacy Variable s ; : The secondary assessments of efficacy were: the proportion of subjects experiencing no nausea during the 24 hours after recovery from anaesthesia; the number of emetic episodes experienced during the 24 hours post recovery period; the highest nausea grade recorded during the 24 hours postrecovery period. Statistical Methods: The primary population for all analyses of efficacy data was the Intention-to-Treat-Population ITT ; , consisting of all subjects who were randomized, who received study medication and who underwent surgery. The primary measure of efficacy was based on the proportions of subjects in each treatment group who experienced complete control of emesis no emetic episodes, no rescue, no withdrawal ; . The proportions of subjects with complete control of emesis were compared within each treatment groups using a Mantel- Haenszel chi-squared two sides test. Secondary measures of efficacy were based on the proportion of subjects in the ITT population who experienced no nausea in the 24 hour post-recovery period. The Mantel-Haenszel chi-squared test, stratified by cluster of centres was used to compare treatment groups. The distribution of the number of emetic episodes and the distribution of the severity of post-operative nausea were compared using Wilcoxon rank sum test. The Wilcoxon test was used to compare the basal nausea grade with the worst nausea grade recorded after therapy, within each treatment groups. Study Population: Male or female subjects aged 18 to 75 years having ophthalmic surgery strabismus, glaucoma, retinal detachment ; , performed under general anaesthesia, who were expected to remain in the hospital for 24 hours post recovery were eligible for study participation. Female subjects who weighed 100Kg, male subjects who weighed 120kg; subjects classified grade 3 or 4 according to the American Society of Anaesthesiologists physical status classification, or who experienced emesis, or who received any drug with known or potential antiemetic activity in the 24 hours prior to study drug administration were among those not eligible for study participation. Ohdansetron Number of Subjects: Planned, N Randomised, N Completed, n % ; Total Number Subjects Withdrawn, N % ; Withdrawn due to Adverse Events n % ; Withdrawn due to Lack of Efficacy n % ; Withdrawn for other reasons n % ; 150 ; 0 0 0 Metoclopramide 150 ; 0 0 0. This was a phase III, multinational, randomized, double-blind, doubledummy, stratified, parallel-group, active-comparator trial conducted between July 2000 and December 2001. Eligible patients were randomized to receive 1 of 3 treatments administered as a single fixed i.v. dose 30 min before chemotherapy initiation on day 1: palonosetron 0.25 mg, palonosetron 0.75 mg, or ondansetron 32 mg. Use of a single dose of prophylactic corticosteroid dexamethasone 20 mg i.v. 15 min before chemotherapy initiation ; was allowed at physician discretion, but not required. Randomization of patients in this study was stratified by factors known to influence emetic risk, including dexamethasone use yes no ; , gender male female ; , and prior chemotherapy naive non-naive ; to ensure balance between treatment groups. Subjects were followed for 5 days for the efficacy endpoints and 15 days for safety endpoints. The study was conducted according to the Declaration of Helsinki, and written approval was obtained from the ethics committees and institutional review boards at each site in all participating countries before study commencement and tacrolimus. Prapasri Thongtawepol. Impact of procurement deregulation on the Government Pharmaceutical Organization's products and structure. Bangkok : Chulalongkorn University, 1997. 120 p. T E12748. Results Experiment 1 Pargyline administration increased 5HT levels drug treatment F 1, 228 ; 5077, P 00001; see Fig. 1 ; , indicating that this monoamine oxidase inhibitor has the expected effect in female Syrian hamsters. There was no effect of time after injection F 3, 228 ; 017, P 09172 5HT levels were maximally increased 10 min after administration of pargyline. There was an effect of brain area F 3, 228 ; 614, P 00005 levels of 5HT measured in the SCN were higher than 5HT levels in the other brain areas examined post-hoc test ; . These data are similar to those reported by Cohen & Wise 1988b ; for the rat. Although 5HT content did not appear to be elevated in the ME 10 min after this injection of pargyline, it certainly was in all other brain areas examined. Thus, to avoid underestimating turnover by choosing a longer period after injection, we chose 10 min post-injection for killing the animals in the subsequent experiment. As is obvious from the results of that experiment, this methodology is sensitive enough to measure increases in 5HT turnover in the ME. Experiment 2 For LH, FSH, and PRL there were significant effects of time of injection LH, F 11, 532 ; 2844, P 00001; FSH. 215. Diemunsch P, Korttila K, Leeser J, Helmers JH, Wilkey B, Nave S, Radke AJ, Hahne WF, Brown RA. Oral dolasetron mesylate for prevention of post-operative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. The Oral Dolasetron PONV Prevention Study Group. J Clin Anesth 1998; 10: 145152. Koivuranta M, Laara E, Ranta P, Ravaska P, Alahuhta S. Comparison of ondansetron and droperidol in the prevention of post-operative nausea and vomiting after laparoscopic surgery in women. A randomised, double-blind, placebo-controlled trial. Acta Anaesthesiol Scand 1997; 41: 12731279. Warriner CB, Knox D, Belo S, Cole C, Finegan BA, Perreault L. Prophylactic oral dolasetron mesylate reduces nausea and vomiting after abdominal hysterectomy. The Canadian Dolasetron Study Group. Can J Anaesth 1997; 44: 11671173. Korttila K, Clergue F, Leeser J, Feiss P, Olthoff D, Payeur-Michel C, Wessel P, Nave S, Hahne W, Brown R. Intravenous dolasetron and ondansetron in prevention of post-operative nausea and vomiting: a multicenter, double-blind, placebo-controlled study. Acta Anaesthesiol Scand 1997; 41: 914 Graczyk SG, McKenzie R, Kallar S, Hickok CB, Melson T, Morrill B, Hahne WF, Brown RA. Intravenous dolasetron for the prevention of post-operative nausea and vomiting after out-patient laparoscopic gynecologic surgery. Anesth Analg 1997; 84: 325 Wilson AJ, Diemunsch P, Lindeque BG, Scheinin H, HelboHansen HS, Kroeks MV, Kong KL. Single-dose i.v. granisetron in the prevention of post-operative nausea and vomiting. Br J Anaesth 1996; 76: 515518. Capouet V, DePauw C, Vernet B, Ivens D, Derijcke V, Versichelen L, van Aken H, Ickx B, Ritter L, Hulstaert F. Single dose i.v. tropisetron in the prevention of post-operative nausea and vomiting after gynaecological surgery. Br J Anaesth 1996; 76: 54 Paech MJ, Pavy TJ, Evans SF. Single-dose prophylaxis for postoperative nausea and vomiting after major abdominal surgery: ondansetron versus droperidol. Anaesth Intens Care 1995; 23: 548 Desilva PH, Darvish AH, McDonald SM, Cronin MK, Clark K. The efficacy of prophylactic ondansetron, droperidol, perphenazine, and metoclopramide in the prevention of nausea and vomiting after major gynecologic surgery. Anesth Analg 1995; 81: 139 Fortney JT, Gan TJ, Graczyk S, Wetchler B, Melson T, Khalil S, McKenzie R, Parrillo S, Glass PS, Moote C, Wermeling D, Parasuraman TV, Duncan B, Creed MR. A comparison of the efficacy, safety, and patient satisfaction of ondansetron versus droperidol as antiemetics for elective outpatient surgical procedures. S3A-409 and S3A-410 Study Groups. Anesth Analg 1998; 86: 731738. Tramer MR, Reynolds DJ, Moore RA, McQuay HJ. Efficacy, doseresponse, and safety of ondansetron in prevention of postoperative nausea and vomiting: a quantitative systematic review of randomized placebo-controlled trials. Anesthesiology 1997; 87: 12771289. Tramer MR, Moore RA, Reynolds DJ, McQuay HJ. A quantitative systemic review of ondansetron in treatment of established post-operative nausea and vomiting. BMJ 1997; 314: 1088 Taylor AM, Rosen M, Diemunsch PA, Thorin D, Houweling PL. A double-blind, parallel-group, placebo-controlled, dose-ranging, multicenter study of intravenous granisetron in the treatment of post-operative nausea and vomiting in patients undergoing surgery with general anesthesia. J Clin Anesth 1997; 9: 658 Alon E, Buchser E, Herrera E, Christiaens F, De Pauw C, Ritter L, Hulstaert F, Grimaudo V. Tropisetron for treating established. Ondansetron is used to prevent nausea and vomiting associated with cancer chemotherapy, radiation therapy, and surgery. The patient subsequently began retching, and an additional 4 mg of ondansetron was administered intravenously and zofran. Ondansetron subcutaneous infusion hyperemesisOndansetron pharmacokinetics3. Antiemetics: Benzquinamide, Chlorpromazine Thorazine ; , Cyclizine Marezine ; , Dimenhydrinate Dramamine ; , Diphenhydramine Benadryl ; , Dolasetron Mesylate Anzemet ; , Dronabinol Marinol ; , Emetrol, Granisetron Kytril ; , Hydroxyzine Vistaril ; Metoclopramide Reglan ; , Ondansetron Zofran ; , Perphenazine Trilafon ; , Prochlorperazine Compazine ; , Promethazine Phenergan ; , Scopolamine Transderm Scop ; , Thiethylperazine Maleate Torecan ; , Trimethobenzamide Tigan.
|